PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
21651476-8	2011	This review mainly reports the recently discovered mTOR ATP-competitive inhibitors in terms of medicinal chemistry, classified by their chemical structures, focusing on SAR and modelling studies that led to the discovery of very potent and selective agents, such as AZD-8055, OSI-027 and INK128, already entered clinical trials, or WYE-132, Torin1 and others in preclinical studies.	WYE 125132	332-339	mechanistic target of rapamycin kinase	Homo sapiens	51-55
20233713-2	2010	Here, employing an mTOR active-site inhibitor WYE-125132 (WYE-132), we have performed quantitative phospho-proteomics and identified a Ser-75-containing phosphopeptide from Maf1, a known repressor of RNA polymerase III (Pol III) transcription.	WYE 125132	46-56	mechanistic target of rapamycin kinase	Homo sapiens	19-23
20233713-2	2010	Here, employing an mTOR active-site inhibitor WYE-125132 (WYE-132), we have performed quantitative phospho-proteomics and identified a Ser-75-containing phosphopeptide from Maf1, a known repressor of RNA polymerase III (Pol III) transcription.	WYE 125132	46-56	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	173-177
20233713-4	2010	WYE-132-induced Maf1 dephosphorylation correlated with its accumulation in the nucleus and a marked decline in the cellular levels of pre-tRNAs.	WYE 125132	0-7	MAF1 homolog, negative regulator of RNA polymerase III	Homo sapiens	16-20
26293898-6	2016	Interestingly, introducing a constitutively active AKT (caAKT), which restored mTORC1/2 activation in WYE-132-treated ovarian cancer cells, only mitigated (but not abolished) WYE-132-mediated growth inhibition and apoptosis.	WYE 125132	175-182	AKT serine/threonine kinase 1	Homo sapiens	51-54
26293898-7	2016	Further studies showed that WYE-132 inhibited sphingosine kinase-1 (SphK1) activity, leading to pro-apoptotic ceramide production in ovarian cancer cells.	WYE 125132	28-35	sphingosine kinase 1	Homo sapiens	46-66
26293898-7	2016	Further studies showed that WYE-132 inhibited sphingosine kinase-1 (SphK1) activity, leading to pro-apoptotic ceramide production in ovarian cancer cells.	WYE 125132	28-35	sphingosine kinase 1	Homo sapiens	68-73
26293898-8	2016	Meanwhile, WYE-132-induced cytotoxicity against ovarian cancer cells was inhibited by sphingosine-1-phosphate (S1P) but was aggravated by SphK1 inhibitor SKI-II or C6 ceramide.	WYE 125132	11-18	sphingosine kinase 1	Homo sapiens	138-143
26293898-10	2016	These results demonstrate that WYE-132 inhibits ovarian cancer cell proliferation through mTOR-dependent and mTOR-independent mechanisms and indicate a potential value of WYE-132 in ovarian cancer treatment.	WYE 125132	31-38	mechanistic target of rapamycin kinase	Homo sapiens	90-94
26293898-10	2016	These results demonstrate that WYE-132 inhibits ovarian cancer cell proliferation through mTOR-dependent and mTOR-independent mechanisms and indicate a potential value of WYE-132 in ovarian cancer treatment.	WYE 125132	31-38	mechanistic target of rapamycin kinase	Homo sapiens	109-113
20068177-0	2010	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	WYE 125132	75-85	CREB regulated transcription coactivator 1	Mus musculus	132-138
20068177-0	2010	Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2.	WYE 125132	75-85	CREB regulated transcription coactivator 2	Mus musculus	143-149
20068177-3	2010	Here, we report WYE-125132 (WYE-132), a highly potent, ATP-competitive, and specific mTOR kinase inhibitor (IC(50): 0.19 +/- 0.07 nmol/L; >5,000-fold selective versus PI3Ks).	WYE 125132	16-26	mechanistic target of rapamycin kinase	Homo sapiens	85-89
20068177-4	2010	WYE-132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo.	WYE 125132	0-7	CREB regulated transcription coactivator 1	Mus musculus	18-24
20068177-4	2010	WYE-132 inhibited mTORC1 and mTORC2 in diverse cancer models in vitro and in vivo.	WYE 125132	0-7	CREB regulated transcription coactivator 2	Mus musculus	29-35
26293898-0	2016	The anti-ovarian cancer activity by WYE-132, a mTORC1/2 dual inhibitor.	WYE 125132	36-43	CREB regulated transcription coactivator 1	Mus musculus	47-53
26293898-6	2016	Interestingly, introducing a constitutively active AKT (caAKT), which restored mTORC1/2 activation in WYE-132-treated ovarian cancer cells, only mitigated (but not abolished) WYE-132-mediated growth inhibition and apoptosis.	WYE 125132	102-109	AKT serine/threonine kinase 1	Homo sapiens	51-54